Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada NHP license regs in effect

This article was originally published in The Tan Sheet

Executive Summary

Health Canada implements the Natural Health Products Unprocessed Product License Applications Regulations, effective Aug. 4, to allow dietary supplements, homeopathics and other NHPs an expedited path to market. In a 1letter, the agency calls the regulations "a temporary solution" - in effect for 30 months - by which applicants seeking a natural health product number instead can receive an exemption number if Health Canada fails to license or reject a product within 180 days (2"The Tan Sheet" June 21, 2010). The agency faces a sizable backlog of license applications and expects the UPLARs to "provide for the legal sale of nearly 12,000 NHPs" that fit a minimum safety profile. The regulations came after Canadian pharmacists objected to Health Canada allowing NHPs with pending licenses to reach retail

You may also be interested in...



Canada Proposes Temporary Expedited Approval For Natural Health Products

Health Canada moves to liberalize, at least temporarily, the approval process by which natural health products come to market to assuage concerns about retailer liability

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Bayer's Efforts To Pioneer Tumor-Agnostic Market In Europe Held Back

Bayer’s drive to lead a new market opportunity in Europe for histology-independent cancer agents like Vitrakvi has been set back by interim decisions from the UK’s NICE and Germany’s IQWiG, but there is a now a clear pathway to follow.

 

Topics

UsernamePublicRestriction

Register

PS104397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel